Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics (DMAC) with an Overweight rating and $25 price target DiaMedica has begun to generate very compelling data for DM199 for treatment of pre-eclampsia, with key opinion leaders indicating a very high unmet need and a very high degree of enthusiasm for this product, the analyst tells investors in a research note. The firm estimates peak sales reaching more than $1B by 2033, but believes this will prove quite conservative.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
- DiaMedica Therapeutics Reports Q3 2025 Financial Results
- DiaMedica Therapeutics’ Earnings Call: Mixed Outlook
- DiaMedica Therapeutics Reports Q3 2025 Financial Results and Clinical Progress
- DiaMedica Therapeutics reports Q3 EPS (17c), consensus (16c)